- Primary hypercholesterolemia- heterozygous familial and non-familial hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb)
- Elevated serum TG levels (Fredrickson type IV)
- Primary dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet.
- Homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (LDL apheresis) or if such treatments are unavailable.
Dosage & Administration
Patients should be placed on a standard cholesterol-lowering diet before receiving Atorvastatin and should continue on this diet during treatment with Atorvastatin . The usual starting dose for all the indications is 10 mg once daily. The doses range is 10 to 80 mg once daily. Doses should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response. Adjustment of dosage should be made at intervals of 4 weeks or more. Doses may be given at anytime of day with or without food.
Children: Treatment experience in a paediatric population with dose of Atorvastatin up to 80 mg/day is limited.
Geriatric (>70 years): The safety and efficacy of Atorvastatin in this population is as similar as < 70 years of age patients with the dose upto 80 mg/day.
In patients with Renal Insufficiency: No dosage adjustment is required.